Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 2Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 79Nasopharyngeal Carcinoma 51Uterine Cervical Neoplasms 44Lung Neoplasms 38Esophageal Neoplasms 32Head and Neck Neoplasms 28Esophageal Squamous Cell Carcinoma 28Squamous Cell Carcinoma of Head and Neck 22Stomach Neoplasms 20Breast Neoplasms 16Small Cell Lung Carcinoma 15Recurrence 12Neoplasm Metastasis 12Nasopharyngeal Neoplasms 12Carcinoma, Squamous Cell 10Ovarian Neoplasms 9Central Nervous System Neoplasms 9Neuroblastoma 8Lymphoma, Large B-Cell, Diffuse 8Pancreatic Neoplasms 7Lymphoma 7Hypopharyngeal Neoplasms 7Triple Negative Breast Neoplasms 6Oropharyngeal Neoplasms 6Neoplasms 6Biliary Tract Neoplasms 6Urinary Bladder Neoplasms 5Lymphoma, Non-Hodgkin 5Lymphoma, Large-Cell, Immunoblastic 5Lymphoma, Follicular 5

Interventions

lenvatinib 3tislelizumab 2sintilimab 2theasinensin A 1sitravatinib 1S 1 (combination) 1Gemcitabine 1Cryosurgery 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Advanced Biliary Tract Cancer × Cisplatin × Clear all
NCT05410197 2022-10-12

Envofolimab and Lenvatinib Combined With Gemcitabine Plus Cisplatin for Advanced BTC as First-Line Treatment(ENLIGHTEN)

Sun Yat-sen University

Phase 2 Unknown
43 enrolled
Gastrointestinal

Advanced Biliary Tract Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡